In the setting of previously proposed models, our data suggest that YKL-40 CSF levels begin to increase before the stage of MCI and keep increasing during the symptomatic stages of AD in contrast to the more classic CSF biomarkers that reach a plateau [21, 36, 41]. The gene discussed is CHI3L1; the disease is Alzheimer disease.